DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Cirmtuzumab
Cirmtuzumab
2015 Post-ASH Report
Tanibirumab (CUI C3490677) Add to Cart
Pre-Clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Role of Non-Coding Rnas in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia
CLL June 18 2014 Slides
2018 Medicines in Development for Cancer
Understanding Mantle Cell Lymphoma: Relapsed/Refractory
FOCUS on NHL/CLL Thursday December 10, 2020 (3 Hrs)
Targeting Cancer
Copyrighted Material
2019 Biomedtracker Datamonitor Healthcare ASCO Planner
This Is an Author Produced Version of a Paper Published in Current Drug Targets
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance
An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
Ampi202018printswap1up 1..76
2020 Medicines in Development ꟷ Cancer
Compilation of Abstract Titles from ASCO Annual Meeting 2021 (Oral, Poster Discussion, Posters, Mains Track by Cancer Types Only)
Top View
New Developments in Lymphoma Therapy Sven De Vos, MD, Phd UCLA Lymphoma Program Los Angeles
WO 2019/075108 Al 18 April 2019 (18.04.2019) W 1P O PCT
Wnt/Β-Catenin Signaling in Cancers and Targeted Therapies
Anti-Alphavbeta3 Monoclonal Antibody EMD 525797 (CUI C2830088) Add to Cart
The Up-To-Date Role of Biologics for the Treatment of Chronic Lymphocytic Leukemia
Targeting Cancer Stem Cells in Cholangiocarcinoma (Review)
Highlights in Chronic Lymphocytic Leukemia from the 2020 American
Lymphoma Care in Europe
7/09/14 a Phase I Clinical Trial
TRIO-US Social Media @TRIO US SMO
WO 2018/136663 Al 26 July 2018 (26.07.2018) W !P O PCT
Highlights in Chronic Lymphocytic Leukemia from the 2021 American